Scribe Therapeutics (SCTX)
Develops CasX-based genetic medicines for lipid-linked cardiometabolic disease.
Something off on this page? Send us feedback.
Develops CasX-based gene-editing and epigenetic-silencing medicines for lipid-linked cardiometabolic conditions, while licensing its platform for partner-led programs. Its wholly owned pipeline is early-stage, and its current revenue comes from collaborations rather than product sales.
Builds CRISPR-based genetic medicines for cardiometabolic conditions around PCSK9, LPA, and APOC3, using compact engineered CasX systems. Its CRISPR by Design process combines protein, guide-RNA, and delivery engineering with machine-learning-assisted design and experimental validation. The wholly owned pipeline pairs epigenetic silencing for PCSK9 with permanent editing programs for LPA and APOC3.
Runs an early human study in Australia for STX-1150, while the other wholly owned programs remain preclinical. It also licenses technology to Sanofi and Lilly/Prevail for sickle-cell, oncology, neurological, and neuromuscular programs, producing collaboration revenue rather than product sales. Development depends on human clinical evidence, partner execution, licensed foundational rights, Acuitas lipid-nanoparticle technology, and external manufacturing.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Not reported.
No dividends on record.
| Strategic holders1 holder · as of Jul 23, 2026 | 6.52% | 1.05M shares | |
| Otherremainder | 93.48% | 15.13M shares |
16.18M company shares as of Aug 21, 2026 · holders as of their latest filing
The share count has not been confirmed by a second filing; stakes use it as it stands.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
ELI LILLY & CoStrategic10 percent owner | 6.52% | 1.05M | Form 4filed Jul 23, 2026 ↗ |
Form 4 — an insider's transaction report
Insider tradesForm 4
Nothing filed in the last 12 months.
- Eli Lilly
One-time PCSK9 editing and Lp(a)-lowering programs.
- Novartis (ADR)
Approved PCSK9 therapy and an Lp(a) program in lipid care.
- Amgen
Approved PCSK9 drug plus a late-stage Lp(a) RNA therapy.
- CRISPR Therapeutics
In vivo liver editing for Lp(a) and severe hypertriglyceridemia.
- Ionis Pharmaceuticals
Same-target APOC3 therapy for severe hypertriglyceridemia.
- Arrowhead Pharmaceuticals
APOC3 siRNA in the same severe triglyceride disorders.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Scribe Therapeutics | $31.00 | +0.62% | $500.0M | — | — | — | — |
| Eli Lilly | $1,165.17 | +0.50% | $1.09T | 38.9 | 28.4 | 13.7 | +47.7% |
| Novartis (ADR) | $161.87 | −0.35% | $308.79B | 24.5 | 17.3 | 5.6 | +0.9% |
| Amgen | $442.21 | −0.14% | $239.00B | 27.5 | 18.9 | 6.3 | +9.7% |
| CRISPR Therapeutics | $56.94 | +0.08% | $5.49B | — | — | 409.9 | +1,041.4% |
| Ionis Pharmaceuticals | $60.74 | −0.93% | $10.19B | — | — | 11.7 | −40.7% |
| Arrowhead Pharmaceuticals | $85.13 | −0.30% | $12.02B | — | — | 18.0 | +171.0% |
| Median | 27.5 | 18.9 | 12.7 | +28.7% |